Operator
Ladies and gentlemen, welcome to the Ambu Earnings Release Q3 2025-’26 Conference Call. I’m Vicki, the Chorus Call operator. [Operator Instructions] The conference is being recorded. [Operator Instructions] The conference must not be recorded for publication or broadcast.
At this time, it’s my pleasure to hand over to Britt Meelby Jensen, CEO. Please go ahead.
Britt Jensen
Chief Executive Officer
Thank you, and good morning, everyone, and welcome to this earnings call for our Q3 ’25-’26 results. My name is Britt Meelby Jensen. I’m the CEO of Ambu, and I have Henrik Skak Bender, our CFO, with me today. So if we move to the next slide and then the next one again, I’ll start with a review of our business and progress before I hand over to Henrik to go through our financials.
And starting on the next slide, please, with the highlights for Q3. Overall, we see a very strong shift towards single-use endoscopy. We continue to lead this conversion to single-use by bringing new innovative solutions to the market that can address a wide range of procedures, also supported by key opinion leaders across the different areas that we are in.
In the quarter, this was most evident in the reacceleration we have seen in Respiratory, which, as you know, is the first area we entered. Here, we grew 17.1%, which was driven by our bronchoscopy portfolio, but supported by the strong synergistic effect from our
